NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BlueWillow Biologics

BlueWillow Biologics

Private
Ann Arbor, MichiganHealthcare & Life Scienceshttps://bluewillow.com/

Last Round

Grant

Oct 1, 2019

Total Funding Raised

$84.83M

Company Overview

BlueWillow Biologics is a biotechnology company that develops intranasal vaccines and adjuvant technology to protect against infectious diseases and food allergies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Defense Tech

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

intranasal vaccinenanoemulsionmucosal immunityvaccine adjuvantbiodefensepandemic preparednessnasal spray vaccinebiopharmaceuticaldrug delivery platformclinical-stage biotechanthrax vaccinenasal deliveryanti-infectivegovernment research grantsneedle-free vaccine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BlueWillow Biologics Comps

Public and private peers based on sector, stage, and business model.

BlueWillow Biologics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

BlueWillow Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 1, 2019
GrantSep 26, 2018
Series AMay 7, 2018
Series CNov 28, 2012
GrantNov 30, 2010
Series B
Jul 8, 2009

Key People

Founding team and executive leadership

Chad Costley

Chief Executive Officer, Board Member

Executive Team

matt lie

CEO

Executive Team

BlueWillow Biologics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2019

    $3.2M grant from National Institute of Allergy and Infectious Diseases.

  • Jul 8, 2009

    $22M round led by Perseus, L.L.C.

BlueWillow Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BlueWillow Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BlueWillow Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAnn Arbor, Michigan
Employee Range22
Year Founded1996
Last FundingOct 1, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.